56242-86-5

Upstream product

• 122-04-3 4-nitro-benzoyl chloride 
• 95-54-5 1,2-diamino-benzene 

Downstream Products

• 217185-14-3 N,N'-di(p-aminobenzoyl)phenylenediamine 
• 2963-77-1 4-(1H-benzimidazol-2-yl)aniline 
• 3717-95-1 1,3-dimethyl-2-(4-nitrophenyl)-1H-benzimidazol-3-ium iodide 
• 729-13-5 2-(4-nitrophenyl)benzimidazole 
• 67944-81-4 N,N'-Bis(4-nitrobenzoyl)-o-benzochinondiimin 

Relevant academic research and scientific papers

PRODRUGS FOR NITROREDUCTASE BASED CANCER THERAPY- 2: Novel amide/Ntr combinations targeting PC3 cancer cells

The use of nitroreductases (NTR) that catalyze the reduction of nitro compounds by using NAD(P)H in GDEPT (Gene-directed enzyme prodrug therapy) studies which minimize toxicity at healthy cells and increases concentration of drugs at cancer cells is remarkable. Discovery of new prodrug/NTR combinations is necessary to be an alternative to known prodrug candidates such as CB1954, SN23862, PR-104A. For this aim, nitro containing aromatic amides (A1-A23) were designed, synthesized, performed in silico ADMET and molecular docking techniques in this study. Prodrug candidates were studied on reduction potentials with Ssap-NtrB by HPLC system. Also, cyototoxic properties and prodrug ability of these amides were investigated using different cancer cell lines such as Hep3B and PC3. As a result of theoretical and biological studies, combinations of A5, A6 and A20 with Ssap-NtrB can be suggested as potential prodrugs/enzyme combinations at NTR based cancer therapy compared with CB1954/NfsB.

Design and synthesis of 2-arylbenzimidazoles and evaluation of their inhibitory effect against Chlamydia pneumoniae

Chlamydia pneumoniae is an intracellular bacterium that responds poorly to antibiotic treatment. Insufficient antibiotic usage leads to chronic infection, which is linked to disease processes of asthma, atherosclerosis, and Alzheimer's disease. The Chlamydia research lacks genetic tools exploited by other antimicrobial research, and thus other approaches to drug discovery must be applied. A set of 2-arylbenzimidazoles was designed based on our earlier findings, and 33 derivatives were synthesized. Derivatives were assayed against C. pneumoniae strain CWL-029 in an acute infection model using TR-FIA method at a concentration of 10 μM, and the effects of the derivatives on the host cell viability were evaluated at the same concentration. Fourteen compounds showed at least 80% inhibition, with only minor changes in host cell viability. Nine most potential compounds were evaluated using immunofluorescence microscopy on two different strains of C. pneumoniae CWL-029 and CV-6. The N-[3-(1H-benzimidazol-2-yl)phenyl]-3-methylbenzamide (42) had minimal inhibitory concentration (MIC) of 10 μM against CWL-029 and 6.3 μM against the clinical strain CV-6. This study shows the high antichlamydial potential of 2-arylbenzimidazoles, which also seem to have good characteristics for lead compounds.

Mass spectrometer as a probe in the synthesis of 2-substituted benzimidazoles

The pyrolysis of N,N'-diacyl-1,2-benzenediamines leads to the formation of 2-substituted benzimidazoles. This new synthetic approach towards the synthesis of 2-substituted benzimidazoles is developed based on the electron impact studies of N,N'-diacyl-1,2-benzenediamines under 70 eV conditions, in which important fragment ions corresponding to 2-substituted benzimidazoles are observed. The mechanisms and ion-structures, proposed in the mass spectral study, are supported by high-resolution, B/E and B2/E linked-scan spectra and Collision Activated Decomposition (CAD)-B/E linked-scan spectra.